BC Psilocybin Exemptions: What Section 56 Access Means for Canadians

# BC Psilocybin Exemptions: What Section 56 Access Means for Canadians

Last updated: 2026-08-01. British Columbia runs two of Canada's most important drug-policy experiments at once: Health Canada's psilocybin exemption pathway and the province's decriminalization pilot. Here's how both actually work — and what they don't cover.

TL;DR

• Section 56 exemptions are Health Canada's case-by-case permission slips for psilocybin access — approved for end-of-life and some treatment contexts, but narrow, slow, and not a general access channel.
• BC's decriminalization pilot (2023–2026) removed criminal penalties for personal possession of small amounts of hard drugs — psychedelics like psilocybin were NOT part of the pilot's covered substances.
• Legal psychedelic access in Canada = exemptions + clinical trials + ketamine clinics; everything else is the same informal supply as everywhere.
• The testing rules apply to every route that isn't a licensed trial.

Section 56 exemptions: how the pathway works

Health Canada can grant a Section 56 exemption under the Controlled Drugs and Substances Act — a permission to possess/use a substance that's otherwise controlled. The psilocybin track has evolved:

• The early wins: the first exemptions were granted for end-of-life distress (2022 onward), then for specific therapeutic contexts. Each grant is individual and time-limited.
• The reality: the process is slow, case-by-case, and doctor-led — a clinician must request the exemption with a clear clinical rationale. It is not "sign up and get access."
• The expansion debate: patient groups and researchers keep pushing for broader categories; Health Canada keeps granting narrowly. There's also a legal angle — court challenges arguing medical need grounds for access have had mixed results.

Translation: if you have a clinician who supports psychedelic-assisted treatment and a documented condition, the exemption path exists — but expect paperwork, timelines, and no guarantee.

The decriminalization pilot: the confusion to clear up

BC's 3-year decriminalization pilot (launched 2023) removed criminal penalties for personal possession of small amounts of opioids, cocaine, methamphetamine, and MDMA — the substances driving the overdose crisis. Psilocybin, LSD, and most other psychedelics were not covered. People routinely (and incorrectly) assume the pilot legalized mushrooms. It didn't.

The pilot also hit its own turbulence — the province tightened rules (drug use restrictions in public spaces) after political pressure, and the federal government has signaled limits on the model. The pilot's legacy is contested: decrim advocates cite reduced stigma; opponents point to unchanged overdose numbers.

What actually works in BC

• Clinical trials: BC institutions have run psychedelic research (including psilocybin for treatment-resistant depression and end-of-life anxiety). Screened, competitive, structured — the same rules as everywhere.
• Ketamine clinics: Vancouver and Victoria host clinics; the clinic vs party dose and bladder risk math applies.
• Harm reduction infrastructure: Vancouver's supervised consumption sites and drug-checking services are among the best in North America — BC actually has public drug-checking technology that most of the US lacks.

For everyone outside the exemption track

Informal supply in BC carries the same variables as anywhere: dose variance, adulterants, and the supply-watch patterns. Reagents (Ehrlich, Marquis), fentanyl strips, and a scale — the standard kit.

Bottom line: BC is Canada's policy frontier — Section 56 exemptions for medical use, a decrim pilot that doesn't actually cover psychedelics, and North America's best harm reduction infrastructure. The exemption path is real but narrow; for everyone else, it's trials, clinics, and testing.